Friday, Cyberonics, Inc. (CYBX) said a retrospective safety and efficacy study of its Vagus Nerve Stimulation Therapy on 507 patients with medically refractory epilepsy showed more than 50% reduction in seizure frequency in 64.6% of patients and more than 70% reduction in 42.1% of patients. The study was conducted by a medical team at NYU Langone Medical Center.
Refractory epilepsy is a form of the common chronic neurological disorder called epilepsy for which seizures are frequent and severe enough to seriously interfere with quality of life.
Robert Elliott, chief resident of Neurosurgery at NYU Langone Medical Center, said, "Our study reviewing more than 700 consecutive VNS Therapy procedures further confirms the safety and efficacy of VNS Therapy for medically refractory epilepsy. Patients evaluated in this study varied in age, seizure frequency and treatment histories, and the vast majority of patients saw significant improvements in their seizure control."
Dan Moore, chief executive officer of Cyberonics, said, "Worldwide, more than 50,000 patients with epilepsy have received VNS Therapy, and a significant majority of these patients are consistently opting to continue treatment, which is evidenced by an initial reimplant rate that exceeds 70%. These findings further establish VNS Therapy as the best option for patients with medically refractory epilepsy who are not candidates for resective surgery or who have failed resective surgery."
The medical team led by Elliott conducted a retrospective review of 507 consecutive patients with refractory epilepsy who underwent a total of 720 VNS-related procedures between November 1997 and April 2008. Outcome analysis was performed on 436 patients who underwent primary implantation at the center and had at least one year of follow-up since implantation. Duration of VNS Therapy ranged from one week to 11.35 years.
Results of the study showed more than 50% reduction in seizure frequency in 64.6% of patients and more than 70% reduction in seizure frequency in 42.1% of patients. Patients who failed intracranial epilepsy procedures prior to VNS Therapy had similar outcomes to those who did not have prior surgery. There were no significant differences in efficacy between adults and children, the Cyberonics noted.
CYBX is gaining $0.31 or 1.72% and is trading at $18.36 on a volume of 17 thousand shares on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.